Efficacy of High-Dose Chemotherapy with Stem Cell Transplant in Advanced Neuroblastoma

A retrospective cohort of 211 pediatric patients with advanced-stage neuroblastoma treated between October 2017 and October 2022 compares two consolidation therapies. Lin Wang authored this study, which reports an overall survival advantage for the transplant group (median 34.7 vs. 26.1 months) but also higher rates of severe toxicities like sepsis and renal toxicity.

Use Cases

• Compare overall survival (OS) and event-free survival (EFS) outcomes between HDC+HSCT and HDC alone treatment groups.
• Analyze objective response rate (ORR) differences post-consolidation therapy.
• Model the risk of specific severe toxicities (e.g., bacterial infection, sepsis, mucositis) associated with the transplant procedure.
• Validate survival analysis techniques using Kaplan-Meier and Cox proportional hazards models on real-world clinical data.

Strengths

• Includes 211 patient records (108 in HDC alone group, 103 in HDC+HSCT group).
• Reports specific statistical outcomes, including hazard ratios (e.g., adjusted HR for OS 0.62) and p-values.
• Compares multiple clinical endpoints: OS, EFS, ORR, and treatment-related toxicities.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is contained in a 23.1 KB DOCX file, suggesting a very limited scope, likely summary statistics rather than patient-level records.

Provenance

Source

figshare

Collection Method

Retrospective cohort study identified from institutional medical records.

Time Range

October 2017 to October 2022

Freshness

Last updated 2026-05-14 04:29:57; freshness should be verified.